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Abstract Participants of the Second International Workshop
(WS) on human chorionic gonadotropin (hCG) of the Inter-
national Society of Oncology and Biomarkers Tissue Differ-
entiation 7 (ISOBMTD-7) have characterized in detail a panel
of 69 antibodies (Abs) directed against hCG and hCG-related
variants that were submitted by eight companies and research
groups. Specificities of the Abs were determined using the
First WHO International Reference Reagents for six hCG
variants, i.e., hCG, hCGn, hCGβ, hCGβn, hCGβcf, and
hCGα, which are calibrated in SI units, and hLH. Molecular
epitope localizations were assigned to the ISOBM-mAbs by
comparing ISOBM-Ab specificity, sandwich compatibility,
and mutual inhibition profiles, to those of 17 reference mono-
clonal (m)Abs of known molecular epitope specificities. It
appeared that 48 Abs recognized hCGβ-, 8 hCGα-, and 13
αβ-heterodimer-specific epitopes. Twenty-seven mAbs were
of pan hCG specificity, two thereof with no (<0.1 %; epitope
β1), 12 with low (<1.0 %; epitopes β2/4), and 13 with high
(>>1 %; epitopes β3/5) hLH cross-reactivity. The majority of
hCGβ epitopes recognized were located in two major anti-
genic domains, one on the peptide chain of the tips of β-sheet
loops 1 and 3 (epitopesβ2–6; 27mAbs) and the second around
the cystine knot (e.g., epitopesβ1,β7, andβ10; 9 mAbs). Four
mAbs recognized epitopes on hCGβcf-only (e.g., epitopes
β11 and β13) and six mAbs epitopes on the remote hCGβ-
carboxyl-terminal peptide (epitopes β8 and β9 corresponding
to amino acids 135–144 and 111–116, respectively). For rou-
tine diagnostic measurements, methods are used that either
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detect hCG-only, hCGβ-only, or hCG together with hCGβ or
hCG together with hCGβ and hCGβcf. Sandwich assays that
measure hCG plus hCGβ and eventually hCGβcf should
recognize the protein backbone of the analytes preferably on
an equimolar basis, should not cross-react with hLH and not
be susceptible to blunting of signal by nonmeasured variants
like hCGβcf. Such assays can be constructed using pairs of
mAbs directed against the cystine knot-associated epitope β1
(Asp10, Asp60, and Gln89) in combination with epitopes β2
or β4 located at the top of β-sheet loops 1+3 of hCGβ
involving aa hCGβ20-25+68-77. In summary, the results of
the First and Second ISOBM TD-7 WSs on hCG provide the
basis for harmonization of specificities and epitopes of mAbs
to be used in multifunctional and selective diagnostic hCG
methods for different clinical purposes.
Keywords hCG variants measurement . Antibody
standardization . Epitope standardization . International
standards for hCG . hCG IRR
Objective
Improving between method comparability for measurement
of the heterogeneous glycoprotein hCG requires harmoniza-
tion of epitopes of the Abs used and broad consensus about
assay specificity. To address this, the Second International
Society of Oncology and Biomarkers Tissue Differentiation
7 (ISOBM TD-7) Workshop (WS) by a three-step algorithm
characterized and epitope typed 69 Abs directed against hCG
and variants submitted by diagnostic companies and research
groups. The results of this WS in combination with those of
the First WS enable recommendations to be made regarding
epitope combinations to be used for the design of immuno-
assays for hCG and its variants [1].
Introduction
Physiology, protein structure, and posttranslational protein
backbone variants of hCG
The glycoprotein hormone hCG is essential for maintaining
pregnancy. Physiologically, it is produced and secreted by
the placental trophoblast and pathophysiologically by tro-
phoblastic cancers and by germ cell tumors of the testis and
ovary [2].
hCG is a protein heterodimer consisting of hCGα
noncovalently linked to the hCGβ subunit. As all glycopro-
tein hormone (GPH) subunits, hCGα and hCGβ share struc-
tural homology with members of the cystine knot growth
factor superfamily that includes nerve growth factor,
platelet-derived growth factor and transforming growth factor
beta [3]. The common structural cystine knot motif consists of
two disulfide bridges that link adjacent antiparallel strands of
the single peptide chain to form a ring that is axially permeated
by a third disulfide bond. This central cystine knot determines
the three-dimensional structure of hCGα and hCGβ. On one
side of the knot, there are two neighboring hairpin-like peptide
loops 1 and 3, which, in hCGβ, are stabilized by a disulfide
bond between Cys 23 and Cys72. The single larger loop 2 is
located on the opposite side of the knot [3].
The subunits are noncovalently linked in antiparallel, i.e.,
a head-to-toe fashion, such that loops 1+3 of one subunit are
adjacent to loop 2 of the other subunit [3]. Loops 1 and 3 of
either subunit and the hCGβ cystine knot, respectively are
the most important antigenic regions [1].
The hCGβ genes have developed from an ancestral LHβ
gene by gene duplications and mutations [4]. The hCGβ
protein is 145 amino acids (aa) in length and encoded by 4
genes and 2 alleles (CGβ6/7, CGβ3/9, CGβ5, and CGβ8),
while hLHβ is encoded by a single gene, CGβ4, on chromo-
some 19q13.3. Thus, hCGβ and hLHβ are highly similar in
protein sequence (>85 %) and are immunologically closely
related. Furthermore, LH and hCG activate the same receptor.
The major structural difference between hCGβ and hLHβ is a
carboxyl-terminal peptide extension of hCGβ (hCGβCTP)
encompassing aa 113–145. hCGβCTP evolved through a
read-through event due to a mutational loss of the stop codon
at the genomic level and the incorporation of a hitherto
untranslated gene sequence into the coding region [5]. Anti-
bodies recognizing epitopes on hCGβCTP are used in a num-
ber of highly specific hCG assays [6]. A single gene on human
chromosome 12q21.1-23 encodes the α-subunit, which is
92 aa in length and common to all four human GPHs [7].
hCG is heterogeneous with respect to protein backbone
structure and carbohydrate content and is best considered as
a complex family of hCG variants occurring in body fluids
and tissues. The unambiguous nomenclature for the most
important hCG forms of the protein backbone developed
by the International Federation of Clinical Chemistry
(IFCC) Working Group for Standardization of hCG Deter-
minations is used here (Table 1 and Fig. 1) [1, 8, 9].
Glycosylation isoforms
hCG subunit folding, assembly, intracellular trafficking, se-
cretion, receptor activation, and half-life in serum is dependent
on glycosylation [10]. Both hCG subunits are glycosylated:
hCGα contains twoN-glycosylation sites at Asn52 and Asn78
that are either mono-, bi-, or triantennary or are sometimes
missing. Most N-linked carbohydrate antennae at Asn13 and
Asn30 of hCGβ are of the bi-antennary type, but malignancy-
associated hCG increasingly carries triantennary carbohy-
drates at Asn30 and fucosylation at Asn13 (Fig. 2). Four
putative O-glycosylation sites are located at Ser121 (core-2),
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Ser127 (core-1), Ser132 (core-1), and Ser138 (core-1) on the
hCGβCTP. The pregnancy associated core-1 glycans on
Ser127 and Ser132 are frequently replaced by core-2 glycans
in hCG synthesized in early pregnancy and by tumors [11].
Due to variability in branching of carbohydrate antennae
and terminal sialylation (8–15 sialic acids), numerous
isoforms exist [11, 12]. The relative proportions of more
extensively glycosylated and terminally sialylated glycosyla-
tion variants change with advancing pregnancy, tumor pro-
gression, and between different tumors [13–15]. Consequent-
ly, acidic variants (av) of hCG (avhCG) produced by testicular
cancer [16], by other tumors, and in early pregnancy [13] have
very low isoelectric points (pIs) and higher MWs [15, 17, 18].
The expression avhCG, describing hCG with complex exten-
sively terminally sialylated carbohydrate antennae, was later
replaced by the term “hyperglycosylated” hCG (hCG-h) [19].
Presently, hCG-h is defined as hCG isoforms carrying a
biantennary core-2 O-glycan on Ser132 that is detected by
immunoassays using a mAb-designated B152 (Fig. 2) [20].
hCG epitopes
Elucidation of the three-dimensional structure of hCG [3]
provided the basis for assignment of immunologically and
Table 1 Nomenclature of hCG
and hCG-related variants (modi-
fied according to [1] with
permission)
Abbreviations and definitions for
hCG and hCG-derived mole-
cules as established by the IFCC
Working Group for Standardiza-
tion of hCG [1, 2].
aa amino acids
Symbol Molecular definition
hCG Intact αβ heterodimer, bioactive
hCGn Nicked αβ heterodimer, nicks in the region of aa hCGβ44-48
hCGβ Intact noncombined free hCGβ-subunit, aa hCGβ1-145
hCGβn Nicked hCGβ, nicks in the region of aa hCGβ44-48
hCGβcf Core fragment of hCGβ; aa hCGβ6-40 linked to hCGβ55-92
hCGα Noncombined free α-subunit of hCG; aa hCGα1-92
Less well-defined hCG variants
hCGβCTP Carboxylterminal extension of hCGβ, aa hCGβ109/114-145
-CTPhCG hCGβ truncated core hCG, missing most of the hCGβCTP (aa hCGβ121-145)
-CTPhCGβ hCGβ truncated core hCGβ (aa hCGβ1-120), missing most of the hCGβCTP
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Fig. 1 Schematic representation of human chorionic gonadotropin β
(hCGβ) protein backbone variants and molecular epitope localizations
on assembled and free hCGβ (amino acids, aa hCGβ1-145), hCGβ
core fragment (hCGβcf, aa hCGβ6-40+β55-92), and the carboxyl-
terminal peptide (hCGβCTP, aa hCGβ109/113-145). Modified according
to [1] with permission (INN). Antigenic determinants are diagrammatically
represented on the linear aa sequence. Non-assembled hCGβ carries nine
epitopes (β1–β9), seven are present also on the hCGαβ-heterodimer
(β1–β5, β8, β9), and all, except those on the hCGβCTP (β8, β9), are
located within the amino acid sequences (aa) of hCGβcf. Four additional
specific epitopes are present on hCGβcf only (β10–β13) but not on intact
hCGβ and hCG. All epitopes that are located on core hCGβ (aa 1–112) are
conformationally dependent and determined by the tertiary protein struc-
ture. Important residues contributing to these epitopes at the primary
sequence level were identified by selective mutational analyses: Pro24,
Val25, Arg68, Gly71, and Gly75 contribute to epitope β3, aa Lys20,
Glu21, Gln22, Gly75, and Asn77 to free subunit epitope β6 and Arg68 to
structurally overlapping epitopes β2, β3, β4, and β5 [22, 42]. hCG-specific
epitope β1 is built up by cystine-knot associated Arg10 and Arg60 and to a
minor extent Gln89 as it does in epitope β7. Asp61 plays a role in free
subunit epitopes β6 and β7 [43]. Major antigenic regions of hCGβCTP are
rather linear in nature and determined by the primary structure: aa
hCGβ133-144 comprising epitope β8, that is substructured into β8,1 to
β8,3 and aa hCGβ113-116 corresponding to epitopeβ9 [21, 24, 29, 50, 71].
Numbers represent positions of amino acid residues in the peptide chain.
The metabolic product hCGβcf consists of two peptide fragments that are
linked via five disulfide bonds (depicted by S–S), and its N-linked carbo-
hydrate antennae are truncated.Open circlesN-linked glycans, filled circles
O-linked glycans
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biologically important domains to the molecular surface of
hCG and hCG-related molecules. Several strategies were
pursued to resolve epitope distribution and arrangement as
well as identification of immunodominant regions. Epitope
localization and sharing of epitopes among hCG, hCG-
variants, subunits, and related hormones like LH and sub-
units were determined using molecular chimeras, hCG me-
tabolites, homologous and heterologous glycoprotein hor-
mones and subunits, chemically modified hormones, proteo-
lytic hormone fragments and synthetic peptides, including
peptide scanning, and most importantly by site-specific mu-
tagenesis of hCGβ. It is important to mention that in three
independent laboratories with different sets of mAbs and
analytical techniques similar epitopes and antigenic domains
were defined (for reviews, see [1, 21].
In previous studies, 26 epitopes on hCG and hCG-related
molecules were defined (for reviews, see [1, 20, 22]). Sixteen
epitopes are located on the intact holo hormone hCG (epi-
topes β1–β5, β8, and α9; α1–α5; and c1–c4). Seven of these
are present on both free and assembled hCGβ (β1–β5, β8,
and α9; Fig. 1 and Table 2).
Antibodies against epitopes β1–β5 recognize a wide
range of hCG and hCGβ variants (pan hCG-mAbs), including
hCG+hCGn+hCGβ+hCGβn+hCGβcf. In a first step, epi-
topes recognized by these mAbs can be discerned by their
cross-reactivity with hLH or hLHβ: Abs directed against (1)
epitopeβ1 have no (<0.1 %), (2) epitopesβ2 and β4 <1%, and
(3) epitopes β3 and β5 >>1 % hLH cross-reactivity. Epitopes
β1–β5 are distributed among two antigenic domains: (1) the
cystine knot (epitopeβ1) and (2) hCGβ loops 1+3 comprising
the neighbouring epitopes β2–β6. Epitopes β8 andβ9 are
located on the hCGβCTP and by definition are specific for
hCG and hCGβ [1, 23, 24].
A number of epitopes are of restricted variant specificity.
Abs against such epitopes are useful for variant-selective
immunoassays designed to measure hCG, hCG+hCGn,
hCGβ, hCGβ+hCGβcf, hCGβcf, or hCGα, respectively,
in the presence of excess of other hCG protein backbone
variants and GPHs.
Epitopes β6 (hCGβ loops 1+3 related) and β7 (cystine
knot related) are shared by free hCGβ and hCGβcf but not
by holo-hCG. Epitopeβ14, which is related to the core region
of hCGβ (amino acids 1–112) and maybe cystine knot-
related, was defined in the First ISOBM WS. It is specific
for free hCGβ and not shared by hCGβcf [1]. Four hCGβcf-
specific epitopes β10–β13 (of which β10 and β12 probably
are hCGβ cystine knot-related, PB unpublished data)
are not present on hCGβ, hCGβn, hCG, hCGn, or on
hLH/hLHβ/hLHβcf. Two epitopes, α6 (hCGα loop 2 related)
and α7 (hCGα carboxyl-terminal related), are specific for
nonassembled hCGα.
Some additional Abs recognize epitopes defined only
broadly at the molecular level, e.g., additional c- or β-
mAbs. Within antigenic domains there seem to be epitopes
that remain to be defined more precisely [1].
Algorithm to define hCG epitopes of ISOBM mAbs (INN)
For the Second ISOBM TD-7 WS on hCG, a previously
reported epitope mapping algorithm [22], whichwas also used
in similar form in the First ISOBM TD-7 hCG WS [1] has
been further refined to reliably characterize the specificities






















Fig. 2 Glycosylation variants of hCGβ (according to [11]). In preg-
nancy-derived hCGβ, the N-linked carbohydrates are of the
biantennary type. O-Glycosylation of hCGβ at Ser 121 always contains
a biantennary core-2 and at Ser 138 a core-1 structure with one or two
sialic acids. Malignancy-derived hCG and very early pregnancy hCG as
compared to middle-to-late pregnancy hCGβ is characterized by in-
creased content of triantennary complex-type N-linked carbohydrates
attached to hCGβ Asn 30 and fucosylated carbohydrates attached to
Asn 13. “Hyperglycosylated” hCGβ contains an increased proportion
of triantennary N-linked carbohydrates (Asn 30); core-2 type O-glycans
at Ser 127, Ser 132, and Ser 138; and fucosylated Asn 13-linked glycan.
Some glycosylation sites were not glycosylated in some variants (Ser
138, Ser 121, and Asn 13). Immunoassays for hCG-h based on mAb
B152 recognize the encircled glycan at Ser 132 and surrounding peptide
structure. The major differences in carbohydrate antennae composition
between early and mid-to-late pregnancy- and malignancy-derived hCG
are depicted in red. Filled square GlcNAc, filled diamond Fuc, empty
square GalNAc, empty circle Man, filled circle Gal, empty diamond
NeuAc
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1. Determination of intraspecies Ab specificities with hCG,
hCG-related variants [six First International Reference Re-
agents (IRR) preparations], hLH and synthetic hCGβCTP
peptides to enable grouping of the mAbs according to
their main specificities (α-, β-, and c-mAbs), and
tentative assignment of epitopes by comparing specificity
profiles to those of reference mAbs with known epitope
recognition
2. Confirmation of epitope recognition and spatial arrange-
ment of epitopes using sandwich assays with mutual
antigen recognition or inhibition by pairs ofmAbs to provide
information about epitope disparity or identity/vicinity
3. Cross-referencing of the ISOBM-Abs’ reaction profiles
in specificity and sandwich assays to those of reference
mAbs recognizing previously defined epitopes.
This approach frequently enabled definitive assignment
of epitopes at the molecular level. In rare cases where no
exact molecular localization could be determined due to the
lack of appropriate reference mAbs, additional circumstan-
tial evidence, e.g., mutual steric inhibition in simultaneous
antigen recognition with mAbs of known epitope
localization or recognition of breakdown products like
hCGβcf or inter-species cross-reactivity, was used to eluci-
date the epitope’s antigenic domain [1].
Materials and methods
ISOBM-Abs: codes and descriptions
Sixty-nine ISOBM-TD-7 Abs were submitted by eight partic-
ipants to Dr. Kjell Nustad at the Central Laboratory, Norwe-
gian Radium Hospital (NRH), Oslo, Norway (see Table 7 in
Appendix). The Abs were assigned code numbers ISOBM-
382 to 450. The panel contained (1) 42 Abs to be tested for
molecular epitope recognition, (2) 10 mAbs that were previ-
ously specificity- and epitope-typed in the First ISOBM TD-7
WS on hCG as blinded internal controls: ISOBM-403 is iden-
tical to reference mAb -435 and corresponds to ISOBM-265
and ISOBM-274 in the First WS, ISOBM-411 is identical to -
275 (First WS), ISOBM-415 to -281; ISOBM-416 to -273;
ISOBM-417 to -276; ISOBM-418 to -280; ISOBM-419 to -
271; ISOBM-420 to -264 and -277; ISOBM-422 to -272, and
Table 2 hCG reference-mAbs: molecular localization of epitopes and specificity patterns (modified according to [1], with permission)
Epitopes mAb Specificities Reference mAbs1) 
Code Molecular 
Localization 




hLH hLH hFSH 
hTSH 









hCG loops 1+3 
hCG 20-25 +  
68-77 
<1% <1% 449/INN-hCG-22 
pan hCG3 441/INN-bLH-1 
4
<1% <1% 445/INN-hCG-24 
5
442/INN-hCG-58 
6 ? ? 437/INN-hCG-64 free hCG
7
Cystine knot 
hCG  61+89 
439/INN-hCG-68 
8 hCG 135-145 450/h54 hCG CTP 













1 hCG loop 1 
hCG 13-22 
INN-hFSH-73
















7 hCG  87-92 ? ? ? FA36 free GPH
c-mAbs
c1 hCG loop 2 
hCG loop 1 
hCG cystine 
knot 
? 447/INN-hCG-10 hCG 
no XR hCGn  
minor XR hLHc2 436/INN-hCG-40, 438/INN-hCG -53
c3 n.t. 446/INN-hCG-45 hCG + hCGn 
no XR hLH 
c4 hCG ?  ? 440/INN-hCG-26 hCG + hCGn + hLH 
GPHα glycoprotein hormone alpha subunit, n.t. not tested
a “INN-” reference mAbs can be obtained from the author (P.B.); filled squares, strong reactivity; open squares, no reactivity; gray squares, minor
reactivity
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ISOBM-424 to -279 [1] (Appendix); and (3) 17 reference
mAbs (ISOBM-434–450) of known specificity and epitope
recognition provided by Dr. Peter Berger from the Institute
for Biomedical Aging Research, Innsbruck (INN), Austria.
The hybridomas producing mouse reference mAbs (INN-
mAbs) against hCG, hCGβ, hCGβcf, and hCGβCTP were
established as previously described [23, 25–31] and specificity,
affinity, and epitope analyses by a panel of immunochemical
techniques (for reviews, see [1, 22]).
The 17 reference mAbs were directed against 15 epitopes
on hCG and hCG-related molecules (Table 2) (for reviews,
see [1, 22]). Ten epitopes were located on intact hCG (epi-
topes β1–β5 and β8; c1–c4), and six of these shared by hCGβ
(β1–β5, and β8). Two Abs recognized epitopes on hCGβ
plus hCGβn plus hCGβcf (β6 and β7). Three reference
mAbs against epitopes β10, β11, and β13 recognized exclu-
sively hCGβcf. MAb FB12 recognizing hCGβCTP epitope
β9 [32], ISOBM-278 (epitope (β8 type 1, β8,1) ISOBM-277
(epitope β8 type 2, β8,2) and ISOBM-267 (epitope β14) [1]
were additionally used as control reagents. No reference or
control mAbs for epitopes α1–α7, β12, and β8/3) were ap-
plied in the specificity and epitope typing experiments.
The Abs were checked for purity by sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE),
the protein content determined by measuring the absorbance
at 280 nm (1 mg/mL=1.43), aliquoted and 1 mg of each sent
to the laboratories of the workshop participants performing
the experimental work: Dr. Phil Hemken, Diagnostic Re-
search and Development, Abbott Diagnostics (ABB); Dr.
Elisabeth Paus, Radiumhospitalet, Oslo University Hospital,
(NRH); Dr. Ulf-Håkan Stenman (UHS), Helsinki University
Central Hospital; and Dr. Wilson Stewart, Ninewells Hospi-
tal and Medical School, Dundee (NHD).
First international reference reagents for hCG and hCG
variants
The new international standards for hCG, nicked hCG (hCGn),
hCGα, hCGβ, hCGβn, and hCGβcf were purified and char-
acterized by the IFCC Working Group for Standardization of
hCG Determinations [9] and adopted by the WHO as the First
IRR for hCG and related variants [33]. The material is intended
for use in the calibration of immunoassays in substance con-
centrations, i.e., moles per liter [6]. One milligram each of the
six First IRRs for hCG and related molecules were kindly
supplied by the NIBSC (Dr. Catharine Sturgeon, CS) to each
of the participants and used to characterize the 69 ISOBM-Abs
(Table 3).
For iodination, FRET and BIAcore® specificity and af-
finity determinations the carrier-free frozen concentrates
(FC) of the six First IRRs were used: hCG (FC 99/688),
hCGn (FC 99/642), hCGβ (FC 99/650), hCGβn (FC 99/
692), hCGβcf (FC 99/708), and hCGα (FC 99/720).
Other hormones and peptides
Human LH (hLH-I-1) AFP4345B for iodination was obtained
from National Hormone & Peptide Program, USA. The pep-
tide hCGβCTP135-145, PGPSDTPILPQ, was ordered from
AltaBioscience, UK. The peptide hCGβCTP109-145, TCD
DPRFQDSSSSKAPPPSLPSPSRLPGPSDTPILPQ, was pro-
vided by Dr. Jean-Michel Bidart.
Biochemical characterization of the mAbs (ABB, NRH)
The mAbs were biochemically characterized by gel perme-
ation chromatography–high performance chromatography
(GPC-HPLC; ABB; Online Resource 1), SDS-PAGE under
reducing (ABB; Online Resource 2) and non-reducing condi-
tions (NRH; Online Resource 3), Ab isotyping (ABB, NRH;
Online Resource 4), isoelectric focusing (IEF; ABB; Online
Resource 5), and finally mass spectrometry (MS; ABB; On-
line Resource 6), which was utilized for further characteriza-
tion of Ab samples where double heavy or double light chain
bands were observed using SDS-PAGE testing.
Determination of Ab specificity, affinity, and epitope
localization (ABB, NRH)
The main specificity profiles of mAbs were determined (1)
by direct binding RIA (DB-RIA) with 125I-labeled hormones
and hormone fragments with excess Ab (Online Resources 7,
8) and (2) with competitive ligand analysis (CLA), a RIA
format, wherein the binding between 125I-hCG and serial
diluted Abs is competed with fixed concentrations of the
six First IRRs of hCG and hCG-related molecules and hLH
(75/552), respectively (Online Resource 9). Cross-reactivity
of the ISOBM-Abs with hLH was determined by titration
RIA (NRH) by comparing titers of 125I-labeled hCG versus
125I-labeled LH (Online Resource 10). Epitope recognition
on the hCGβCTP by ISOBM-Abs was evaluated by com-
petitive RIAwith synthetic peptides (NRH; Online Resource
Table 3 The WHO 1st IRRs for hCG and related variants and 5th IS for
hCG
Symbol WHO code Content/ampoule
hCG 5th IS 07/364a 0.39 nmol or 179 IU
hCG 1st IRR 99/688 1.88 nmol
hCGn 1st IRR 99/642 0.78 nmol
hCGβ 1st IRR 99/650 0.84 nmol
hCGβn 1st IRR 99/692 0.88 nmol
hCGβcf 1st IRR 99/708 0.33 nmol
hCGα 1st IRR 99/720 1.02 nmol
a The 1st IRR 99/688 for hCG has been adopted as the new 5th IS 07/
364 for hCG
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11). Ab affinities were determined by Forster Resonance
Energy Transfer (FRET) (ABB; Online Resource 12) and
by BIAcore® (NHD; Online Resource 13). For elucidation
of the spatial arrangement of epitopes, Ab compatibility in
antigen recognition was evaluated by sandwich RIA (NRH;
Online Resource 14).
Results
Biochemical characterization of the mAbs (ABB; NRH)
Gel permeation chromatography–high performance
chromatography (ABB)
The homogeneity of the mAbs determined by GPC ranged
from 57 to 99%with varying degrees of aggregation and low
MW contaminants (Fig. 3a; Online Resource 15). All sam-
ples exhibited low MW peaks possibly caused by buffer
components (azide, citrate, DTT, etc.).
Sodium dodecyl sulfate polyacrylamide gel electrophoresis
(NRH, ABB)
SDS-PAGE analysis was performed under nonreducing (On-
line Resource 16a; NRH) and reducing conditions (Online
Resource 16b; ABB). The purity of the mAbs determined as
the proportion of heavy and light chains relative to all protein
bands ranged from 84 to 100 % (Online Resource 16b). An
example for slight albumin impurity is shown in Fig. 3b. The
appearance of double chains could be due to glycosylation
differences [34, 35], amino acid residue issues [34, 35], or
the presence of more than one Ab in the sample (Online
Resource 16b).
Isoelectric focusing (ABB)
The isoelectric point (pI) of the Abs ranged from 5.0 to 7.7
(Fig. 3c; Online Resource 17). Those for ISOBM-397,
ISOBM-418, and ISOBM-431 could not be determined.
The smearing or absence of bands was probably due to low
solubility of these Abs at the low ion strength in IEF.
Isotyping (ABB)
Isotyping was performed on samples displaying double
heavy or light chains in SDS-PAGE analysis (Table 4).
Mass spectrometry analysis (ABB)
Apart from the following exceptions most ISOBM-Abs gave
expected results. ISOBM-382 had double light chains, and
more than one group of heavy chains present following
deglycosylation, suggesting presence of two mAbs. ISOBM-
385 had two groups of heavy chains due to glycosylation and
ISOBM-388 two nonglycosylated light chains due to amino
acid residue differences. ISOBM-400 and ISOBM-406 had





















Fig. 3 Biochemical characterization of ISOBM-435 by GPC-HPLC
(a), reduced SDS-PAGE (b), and IEF (c). a Percent purity by GPC-
HPLC analysis is 96 % with 7 % aggregation and a small amount (2 %)
of low molecular weight (LMW) contaminants. The LMW material
could be sodium azide and residual albumin, but this was not con-
firmed. b Reduced SDS-PAGE analysis shows a combined heavy and
light chain purity of 96 %. The first strip has been enhanced to increase
the image contrast to highlight a faint band (<1 %) that has a similar
molecular weight as the albumin standard (66 kDa). The second strip
utilized the auto-scale feature available with Quantity One software
(Bio-Rad). A 1 % band is noted at approximately 76 kDa, and a 3 %
band is also seen at approximately 47 kDa. c IEF reveals a tight pI range
of 5.9–6.0.
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Table 4 ISOBM-Abs, biochemical characterization (ABB)
ISOBM GPC-HPLC TOSOH G3000 SWxl columna SDS-PAGEb Isotypeb Phastsystem IEFb
Code % Purity % Aggregation % Low MWc % Purity Heavy/light chain
determination
pI range
382 95 5 <1 99d IgG1, kappa 5.8 – 6.2
383 98 NDe 1 100 IgG1, kappa 6.2–6.8
384 97 2 <1 95 NTf 5.1–5.3
385 97 2 1 100g IgG1, kappa 6.9–7.7
386 89 10 <1 96 NT 6.7–7.2
387 98 1 <1 100 NT 6.0–6.4
388 97 2 <1 99d IgG1, kappa 6.3–7.2
389 98 1 <1 99 NT 5.9–6.2
390 98 1 <1 98 NT 6.8–7.6
391 90 1 9h 100 NT 6.4–7.4
392 92 7 <1 94 NT 5.5–5.9
393 83 5 12i 97 NT 5.6–6.0
394 88 <1 11h 100 NT 6.7–7.3
395 97 3 <1 100 NT 6.9–7.5
396 98 2 <1 99 NT 6.2–6.5
397 96 3 <1 99 NT Indistinctj
398 97 2 <1 99 NT 6.2–6.6
399 88 11 <1k 99 NT 6.4–6.7
400 96 2 2 96d IgG1, kappa 6.1–6.6
401 98 2 <1 98 NT 6.6–7.3
402 97 1 1 100 NT 6.5–7.2
403 97 2 <1 100 NT 6.0–6.3
404 98 2 <1k 99 NT 6.2–6.8
405 94 5 <1k 99 IgG1, 2a, 2b, kappal 5.5–5.8, 6.1–6.6m
406 71 ND 29h 100d IgG1, kappa 5.0–5.3
407 91 8 1k 99 NT 6.2–6.6
408 89 1 10h 100 NT 6.1–6.4
409 64 ND 36h 100 NT 6.1–6.4
410 99 1 <1 99 NT 6.8–7.3
411 94 ND 6n 96, 2o NT 6.0–6.3
412 95 1 3h,p 94 NT 5.4–5.7
413 90 7 2h 99 NT 6.5–7.2
414 86 5 10h 96 NT 6.1–6.4
415 98 <1 1h 100 NT 6.0–6.3
416 74 <1 26h 99 NT 5.8–6.2
417 97 1 2n 99, 1o NT 6.3–6.6
418 99 <1 <1 98 NT Indistinctj
419 86 3 10h 96 NT 5.6–6.0
420 99 <1 <1 100 NT 6.6–7.5
421 97 2 <1 100 NT 6.1–6.6
422 83 1 16h 100 NT 5.6–6.0
423 96 2 1h 99 NT 6.1–6.5
424 98 <1 <1 99 NT 6.2–6.8
425 98 <1 1 100 NT 6.0–6.7
426 98 1 1h 100g IgG1, kappa 6.1–6.4
427 97 2 <1h 99 NT 6.0–6.5
428q 81 11 8n 98, 2o NT 6.0–6.1
429q 92 4 3 100 NT 5.9–6.1
430q 97 1 2 100 NT 6.0–6.2
431q,r 89 ND ND 100 NT ND
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Table 4 (continued)
ISOBM GPC-HPLC TOSOH G3000 SWxl columna SDS-PAGEb Isotypeb Phastsystem IEFb
Code % Purity % Aggregation % Low MWc % Purity Heavy/light chain
determination
pI range
432 95 4 1 99 NT 6.5–7.0
433 97 2 <1 99 NT 5.8–6.2
434 88 4 7n 91, 2o NT 6.1–6.3
435 91 7 2n 96, 1o NT 5.9–6.0
436 86 13 1n 86d,g, 1o IgG1, lambda and kappas 5.7–6.1
437 88 10 <1 96 NT 6.0–6.3
438 87 11 1n 96, 1o NT 5.5–5.7
439 93 5 1n 95, 1o NT 6.3–6.9
440 93 2 5n 91d, 2o IgG1, kappa 5.9–6.0
441 83 12 5n 94, 2o NT 6.2–6.5
442q 57 35 8i,n 85d, 1o IgG1, kappa 5.4–5.7
443 90 9 1 99 NT 6.3–6.6
444 93 4 3n 95, 1o NT 6.0–6.3
445 72 25 3n 84, 3o NT 5.3–5.5
446 95 3 2n 97 NT 6.1–6.4
447 97 2 <1 98 NT 6.3–6.6
448 92 3 5n 87g, 3o IgG2a, kappa 5.8–6.9
449 87 12 <1 95 NT 6.1–6.5
450 89 3 7i,n 90d IgG1, kappa 6.0–6.7
a GPC-HPLC samples were run in triplicate. Mean values are ±1.9 %, which is established from the largest standard deviation (SD) observed.
Triplicate injections of sample 442 had the largest SD of 1.91.
b Single lanes or strips were run for these tests, to preserve sample for additional testing.
c All the samples have peaks with the same retention time as sodium azide. The presence of sodium azide could not be confirmed due to lack of
sample volume to perform additional testing.
d Double light chains. Possible causes for double chains include but are not limited to; glycosylation differences, amino acid residue differences or
more than one antibody present in the sample
e Not Detected
f Not Tested, only samples exhibiting double heavy or light chains by SDS-PAGE or multiple clusters of bands by IEF underwent isotype analysis.
g Double heavy chains.
h These samples have peaks that could represent high levels of residual citrate in these samples. Residual testing would need to be performed to
confirm this. Testing was not performed due to lack of sample volume. High levels of citrate can react with iron that may be present in HPLC
equipment forming iron-citrate complexes. This phenomenon has been observed in other samples containing high citrate levels at retention times of
approximately 11.3 minutes using a G3000SWxl Column and our Waters HPLC system.
i A tailing shoulder is present behind the main antibody peak.
j The sample only produced a smear, possibly due to a high salt concentration.
k Retention times of 9.2 to 9.6 minutes correspond to a molecular weight of 20–30 kDa and could represent free light chain material. The molecular
weight determination was obtained by plotting the logarithm of the GFS molecular weights versus their retention times.
l Two types of heavy chain isotypes indicate this sample is probably not derived from a single clone.
m Two pI ranges indicate this sample may not be derived from a single clone.
n These samples have peaks that have a similar retention time as albumin. The presence of albumin could not be confirmed due to lack of sample
volume to perform additional testing.
o A band was observed near the albumin standard.
p These samples have peaks that have a similar retention time as DTT. The presence of DTT could not be confirmed due to lack of sample volume to
perform additional testing.
q Sheep Antibody
r The label concentration may be incorrect. The observed signals were not consistent with the label concentration.
s Two types of light chain isotypes indicate this sample is probably not derived from a single clone.
GFS Standards: thyroglobulin MW 670,000, RT 6.0–6.1; gamma-globulin MW 158,000, RT 7.9–8.0; ovalbumin MW 44,000, RT 9.2–9.3,
myoglobin MW 17,000, RT 10.3–10.4, vitamin B12 MW 1,350, RT 11.9–12.0
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glycosylation and ISOBM-426 complex heavy chains and
ISOBM-450 complex light chains (Online Resource 18).
Ab affinities, specificities, and epitope localizations
Ab specificities (NRH) Based on the results of DB-RIAs with
125I-labeled hCG, hCG-variants, and hLH tracers, the 69
ISOBM-Abs were categorized according to their main speci-
ficities (α-, β-, and c-mAbs) (Fig. 4): Antibodies either rec-
ognized (a) assembled and/or free hCGα (hCGα-mAbs, n=8;
α epitopes were not determined) or (b) assembled and/or free
hCGβ or hCGβ metabolites such as hCGβcf (hCGβ-mAbs,
n=48; epitopes β1–β13), or (c) exclusively the intact±nicked
hCGαβ heterodimer, but not the free subunits or metabolic
variants thereof (c-mAbs, n=13; epitopes c1–c4).
Comparing specificity profiles of ISOBM-Abs to those of
reference mAbs permitted preliminary epitope assignment.
To discern mAbs against epitopes β1–β5, hLH cross-
reactivity was determined by titration RIAs with 125I-hLH
(Fig. 4). Recognition of hCGβCTP was investigated by
competitive RIA using synthetic peptides derived from
hCGβCTP (Fig. 4a; Online Resource 19). No mAbs against
epitope β14 (hCGβ specific) were identified in this ISOBM
panel (Fig. 4a).
Ab affinities and specificities as determined by FRET (ABB) The
ISOBM-Abs were grouped according to their specificity pro-
files based on affinity for hCG, hCGβ, hCGβcf, and hLH
(Fig. 5) determined by FRET. Affinities for the major hCG
variants and hLH, reported as dissociation constants (Kd),
ranged from subpicomolar values (0.3 pmol/L for hCGβ of
ISOBM-429) to ≥50 nmol/L. The latter value indicated that
binding was very weak or not detectable.
Only nine Abs (ISOBM-387, ISOBM-399, ISOBM-401,
ISOBM-414, ISOBM-416, ISOBM-427, ISOBM-428, ISO
BM-429, and ISOBM-444) expressed high affinities (Kd,
≤50 pmol/L) for any of the four antigens tested (hCG, hCGβ,
hCGβcf, and hLH). It is striking that six of these mAbs
recognize the major antigenic domain on the tips of hCGβ
loops 1+3. An exception was the hCGβcf-specific mAb ISO
BM-444 (reference mAb INN-hCG-106), the epitope of
which (β11) does not overlap with epitopes β2–β5 on hCGβ
loops 1+3 nor with the cystine knot-associated epitopes β1
and β7. Thus, this epitope is remote from either cluster. This
is an interesting mAb for highly sensitive and specific mea-
surement of hCGβcf in particular in combination with β2-
mAbs [9, 36].
Another interesting observation is that all three sheep
mAbs, ISOBM-428, ISOBM-429 and ISOBM-430, were in
the high affinity group. ISOBM-430 was not tested by the
FRET technology but by titration RIA. All four sheep Abs
(three mAbs and polyclonal ISOBM-431) were directed
against hCGβ loops 1+3 epitope β5 that is shared by hLH
and, therefore, in principle, do not seem suitable for hCG
measurement. Nevertheless, ISOBM-429 seems to have tol-
erably low cross-reactivity with hLH (Figs. 4a and 5 and
Online Resource 20), but its suitability for use in hCG+hCGβ
variant measurement might still be hampered by preferential
recognition of hCGβ.
Fig. 4 Specificity profiles of the ISOMB-Abs of the Second TD-7 WS
recognizing hCG and hCGβ variants (a), hCG-only and hCGα, respec-
tively (b) were determined by binding of iodinated tracers to excess of
Ab (DB-RIA) (NRH). ISOBM-mAbs were classified according to their
main specificities and their epitopes recognized on the basis of cross-
reactivity patterns with hCG, hCG-variants, and hLH: (1) β-mAbs
corresponding to epitopes β1–β13, (2) c-mAbs recognizing epitopes
c1–c4 on holo-hCG only, and (3) α-mAbs. a MAbs directed against
epitopes β1–β5 are pan-hCG reagents recognizing hCG and hCGβvariants
but differ in their cross-reactivity with hLH:β1 mAbs are highly specific for
hCG and show no hLH cross-reactivity (<0.1%), β2 andβ4 show very low
hLH reactivity (<1 %), whereas β3 and β5 strongly cross-react (>>1 %).
Epitopes β6 and β7 are specific for uncombined hCGβ, hCGβn, and
hCGβcf. MAbs against epitope β8 at the very carboxyl-terminal end of
hCGβCTP do not cross-react with hCGβcf and hLH but recognize all other
hCG variants except for those lacking the CTP. These mAbs constantly
show a low bindable fraction of the tracers as only approximately 50 % of
the tracers can be bound specifically. This is in contrast to theβ1–β5 mAbs.
ISOBM-418 seems to be directed against epitope β9 as already typed
previously in the First WS (ISOBM-280, [1]. Epitopesβ10–β13 are specific
for hCGβcf as no other hCG variants or hLH are recognized by the
respective mAbs. b c-mAbs directed against epitopes determined by the
quaternary structure of hCG either do not (c1 and c2) or do recognize hCGn
(c3 and c4) [56]. The apparent hCGn cross-reactivity of c1 and c2 mAbs is
due to a cross-contamination of this preparation with non-nicked hCG
(approximately 20 %) [1]. The presence of non-nicked hCG and recogni-
tion by the ISOBM-mAbs of the two-nicked forms in hCGn were investi-
gated in detail by LC-MS/MS (see accompanying publication by H. Lund).
Epitope c3 (ISOBM-446=INN-hCG-45, reference mAb) is highly specific
for hCG+hCGn. ISOBM-mAb 433 that has the same specificity pattern
might be directed against a fifth sterically independent c-epitope as shown
by sandwich assay. The exact molecular localization of epitope c4 on hCG
is not known, but it is remote from the other c-epitopes. In the First ISOBM
TD-7 WS, ISOBM-424 has been characterized (ISOBM-279) and classi-
fied as c4 specific [1]. Theα-mAbs have not been investigated in detail as to
their epitope recognition. As they readily recognized iodinated tracers (in
contrast to α3- and α5-mAbs), they should be directed against the epitope
cluster α1/α2/α4 with the exception of ISOBM-404 that is free hCGα-
specific and therefore presumably recognizing the subunit assembly region
of hCGα (aa hCGα33-42). Minor apparent cross-reactivity with hCGn is
owed to a cross-contamination of hCGα in that preparation. hLH cross-
reactivity of ISOBM-404 might be due to dissociation of highly purified
hLH that is observed during testing (PB, personal observation). DB-RIA
with 125I-tracers: results are expressed as maximum specific binding in
percent of the “bindable fraction” of added tracer (NRH) [26]. Italics RIA
titration experiments (NRH): Results are expressed as percent hLH cross-
reactivities compared to hCG; asterisk 125I-tracers; gray background sig-
nificant cross-reactions. Superscripted a Apparent cross-reactivities with
hCGn of ISOBM-447–438 are caused by an approximate 20 % cross-
contamination of intact hCG (see accompanying publication by H. Lund)
and superscripted b of ISOBM-383–404 due to a suchlike with hCGα
that is contained in hCGβn; superscripted c ISOBM-404: apparent cross-
reactivity is probably caused by slight dissociation of α-subunit in hLH.
Section symbolCompetitive RIAwith hCGβ109-145 vs. hCGβ*, percent
cross-reactivity.Double section symbolCompetitive RIAwith hCGβ135-
145 vs. hCGβ*, percent cross-reactivity

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Most Abs, including all directed against the cystine knot-
associated epitopes β1 and β7, the hCGβCTP epitope β8 types
1 and 2, showed moderate affinities (50 pmol/L–5 nmol/L)
against their primary target hCG variant. Low affinities could
be observed for three reasons: (1) the primary antigenic target
hCG variant of the mAb in question was not among the
antigens tested, as is the case of mAbs against uncombined
hCGα (ISOBM-404), or (2) genuine low affinity to the primary
target antigens, e.g., ISOBM-418/280 (hCGβCTP epitope β9,
aa hCGβ113-116) and ISOBM-443 and 448 against hCGβcf,
and (3) FRET labeling affected binding of Abs (ISOBM-445 to
hCGβcf; ISOBM-399, ISOBM-436, ISOBM-412, and ISO
BM-421 to hLH) (Fig. 5). This is also the case with 125I-
labeling of epitopes α3 and α5 [37].
Ab affinities and specificities as determined by BIAcore®
(NHD) The specificity patterns of the ISOBM-Abs were
determined based on their affinity for hCG, hCGβ, and
hCGβcf in BIAcore®. The affinities (dissociation constants;
Kd) ranged from picomolar values (<10 pM for hCG of
ISOBM-399) to >10 nM. An affinity of <100 nM was
observed for 43 of the Abs for either a single or a combina-
tion of the three antigens tested (hCG, hCGβ, and hCGβcf).
Five of these Abs, ISOBM-427 (epitope β2), ISOBM-399,
ISOBM-423, ISOBM-441 (all three epitope β3), and
ISOBM-428 (epitope β5) had affinities of <10pM for the
antigen. It is striking that all of these recognize the tops of
hCGβ loops 1+3; thus, all epitopes were located within the
same antigenic domain. Assignment of epitopes to the
ISOBM-Abs was achieved by comparing their specificity
profiles to those of reference mAbs (Online Resource 20).
The affinity of many of the ISOBM-Abs appeared to be
higher than determined by FRET analysis. This could per-
haps be a consequence of having the antigen in a bound form
on the BIAcore® chip rather than in a fluid state. The affinity
for this immobilized form of antigen may result in an
overestimate of affinity.
Ab specificities as determined by CLA (NHD) In the CLA
approach, ISOBM-Abs were titrated against 125I-hCG and in
parallel competed with a fixed amount (0.5 pmol/mL) of
hCG, hCG-variants, and hLH, respectively. A shift of the
Ab dilution curves to a lower titre indicated cross-reactivity
of this competitor with the Ab. Based on the CLA results, 34
ISOBM-Abs, either recognized (a) assembled and/or free
b
Fig. 4 (continued)
Fig. 5 Affinity and specificity of the ISOBM-Abs as determined by
FRET (ABB). Preliminary assignment of epitopes was done by com-
paring the specificity profiles of the ISOBM-Abs to those of reference
mAbs. Specificities based on affinity of mAbs against hCGα could not
be determined with hCG, hCGβ, and hCGβcf
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403 1.17 0.65 0.29 >50
435* 1.15 0.52 0.32 >50
382 0.66 0.51 0.16 3.90
388 0.14 0.11 0.11 24.00
390 0.14 0.10 0.07 >50
402 0.08 0.06 0.18 16.90
408 0.10 0.48 0.40 >50
416 ? 0.04 0.02 >50
417 0.37 0.30 0.10 >50
426 0.13 0.17 0.25 >50
427 0.08 0.04 0.03 >50
449* 0.34 0.15 0.15 12.30
396 0.20 0.94 0.90 0.17
399 0.13 0.03 0.02 ?
400 1.60 0.35 0.23 0.33
401 0.86 0.08 0.01 0.30
405 0.17 0.13 0.19 0.50
423 0.06 0.06 0.10 0.10
434* 11.60 16.50 6.10 3.60
441* 5.40 0.75 1.20 0.70
419 0.34 0.35 0.23 >50
445* 0.78 0.76 ? >50
428 sheep 0.01 0.003 0.01 0.10
429 sheep 0.004 0.0003 0.03 0.40
430 sheep n.d. n.d. n.d. n.d.
431 sheep 0.35 0.14 0.20 0.60
442* 0.36 0.25 0.07 0.10
410 49.00 0.08 0.07 >50
437* >50 2.75 3.75 >50
386 6.32 0.23 0.50 >50
397 >50 4.99 8.60 >50
407 >50 0.70 >50 >50
409 >50 1.32 1.55 >50
415 40.40 1.27 4.83 >50
439* >50 0.54 1.92 >50
450* 0.23 2.88 >50 >50
395 0.25 1.93 >50 >50
413 0.54 1.74 >50 >50
420 0.32 1.89 >50 >50
394 0.09 0.67 >50 >50
418 >50 >50 >50 >50 ? _
392 >50 12.40 >50 >50 _
406 0.16 0.23 >50 >50 _
384 >50 >50 4.10 >50
393 >50 >50 4.00 >50
443* >50 >50 >50 >50
444* >50 >50 0.05 >50
448* >50 >50 >50 >50
414 0.01 >50 >50 0.04
447* 0.44 >50 >50 3.00
387 0.05 >50 >50 1.20 hLH
411 2.45 >50 >50 >50
422 0.06 >50 >50 21.80
425 0.12 >50 >50 2.10
436* 0.35 >50 >50 ?
438* 0.06 >50 >50 0.50
446* 1.07 >50 >50 >50 _ c3
424 0.29 >50 >50 >50 _
440* 3.55 >50 >50 1.00 hLH
389 0.19 35.70 >50 >50
433 0.35 >50 >50 >50
383 0.30 >50 >50 0.24
385 0.07 >50 >50 0.12
391 0.05 >50 >50 0.09
398 15.00 29.00 >50 3.80
412 0.29 >50 >50 ?
421 0.20 >50 >50 ?
432 0.34 >50 >50 0.60
404 >50 >50 >50 28.00 _ α6
*reference antibodies Key (kD)
< 0.05 nM
0.05 - 0.5 nM
0.51 - 5 nM





































Tumor Biol. (2013) 34:4033–4057 4045
hCGβ metabolites such as hCGβcf (hCGβ-mAbs, n=24;
epitopes β1–β9) or (b) exclusively hCG±hCGβ, but not the
free subunits (c-mAbs, n=10; epitopes c1–c4). Epitope as-
signment was achieved by comparing profiles of the refer-
ence mAbs with ISOBM-Abs (Online Resource 20).
No CLA analysis was possible for 35 ISOBM-Abs, which
had very low or no signal, which suggested that the Ab did
not recognize 125I-hCG or could not be competed with the
amounts utilized.
Epitope classification by sandwich assays (NRH) IRMA-
like sandwich assays were performed to confirm preliminary
Ab epitope classifications by specificity assays and to
determine epitope localization by comparison with ref-
erence mAbs. Characteristic reaction patterns were ob-
served when solid-phase bound ISOBM-mAbs were
tested for their ability to sandwich hCG or hCGβ with
the panel of reference mAbs directed against epitopes
β1–β9 (Fig. 6a) and c1–c4 (Fig. 6b). Patterns observed
agreed with previously determined epitope locations for
the reference mAbs [28, 38].
Compatibility of Ab pairs in sandwich assays indicated
that their epitopes were spatially distinct, e.g., epitopes β1
versus β2–β6 and vice versa (Fig. 6a). Identical or highly
similar compatibility patterns of Abs to that of reference or
other mAbs indicated recognition of identical or of neigh-
boring epitopes within the same antigenic domain: e.g., the
cystine knot-related epitopes β1 and β7, or epitopes β2, β4,
and β5 on hCGβ loops 1+3. Epitopes within a particular
antigenic domain can be easily discerned by cross-reactivity
patterns with hCG variants and LH from various species [1].
Thus, although β1- and β7-mAbs show identical compatibil-
ity patterns in sandwich assays and are not compatible with
each other (Fig. 6a), they recognize different but spatially
adjacent cystine knot-related epitopes reflected by differing
variant recognition patterns: β1-mAbs recognize a broad
spectrum of hCG-variants whereas β7-mAbs are highly se-
lective for hCGβ, hCGβn±hCGβcf and do not recognize
hCG (Fig. 4).
Antigenic domains and epitope maps of hCG and hCGβ
(INN) Results of the three approaches for epitope typing
are summarized in Table 5. In Fig. 7, the ISOBM-mAbs are
assigned to the three-dimensional epitope maps of hCGβ (a)
and hCG (b), which were established with the reference
mAbs previously [1]. The Abs grouped according to epitope
recognition are listed in Table 8 in Appendix.
In the ISOBM panel, 48 out of 69 were β-Abs. The major
antigenic domain on hCGβ located on the tips of the neigh-
boring β-sheet loops 1 and +3 encompassing aa hCGβ20-25
and 68–77 (epitopes β2–β6) was recognized by 27 of the β-
Abs. Of these, 12 Abs recognize epitopes β2 or β4 (β2/4), 13
epitopes β3 or β5 (β3/5), and 2 epitope β6. Epitopes β2–β5
Fig. 6 Classification and spatial relationship of ISOBM-mAb epitopes.
Two-site IRMA-like sandwich assay experiments with a chessboard-
like matrix of antibody pairs tested for their ability to simultaneously
bind hCGβ (99/650) for hCGβ-mAbs (a) and hCG (99/688) for holo
hCG-mAbs (b) (NRH). Reference Abs for epitopes β1–β9 and c1–c4
served as 125I-labeled detection reagents, respectively. Reaction profiles
of the solid-phase ISOBMii mAbs with the detection reference mAbs
were cross-matched to that of solid-phase reference mAbs the molecular
epitope specificity of which had previously been defined [1]. Similar
reaction profiles were interpreted as epitope identity or neighborhood of
mAbs. a The compatibility patterns of pairs of mAbs do not only reveal
epitope affiliation of single mAbs but also disclose hCGβ epitope
arrangement in larger antigenic domains consisting of one or more
epitopes. Abs directed against epitopes located within the same anti-
genic domain are generally mutually exclusive in hCGβ recognition,
whereas those the epitopes of which are located in different domains are
compatible. Three major antigenic domains were identified on hCGβ:
(1) the domain on the tips of hCGβ loops 1+3 encompassing epitopes
β2–β6 (2) the cystine knot associated domain including hCG specific
epitope β1, hCGβ+hCGβcf specific epitope β7, and a structurally
related hCGβ-only specific epitope epitope β14 located on core
hCGβ1-112 and characterized by a single mAb, and (3) hCGβCTP
epitopes β8 and β9 remote from the other domains. MAbs against all
hCGβ loops 1+3 associated epitopes β2–β6 are compatible with the
hCG-specific cystine knot-associated epitope β1 and vice versa. Within
antigenic domains not all epitopes can be discerned by distinct reaction
profiles. As an example, although β1 and β7 show identical patterns in
sandwich assays and are not compatible with each other, they are
definitely recognizing different but adjacent epitopes as β1-mAbs are
pan-hCGβ-mAbs recognizing a broad spectrum of hCG-variants and in
contrast β7-mAbs are highly selective for hCGβ+hCGβcf and would
not recognize, e.g., hCG (see, e.g., DB-RIA, Fig. 4). A second example
are mAbs against epitopes β4 (ISOBM-419 and ISOBM-445) and β5
(ISOBM-428, ISOBM-429, ISOBM-430, ISOBM-431, and ISOBM-
442) having an identical compatibility profile, i.e., nicely work with
mAbs against epitopes β1 and β7–9 but not with β2–β6. These epitopes
can be discerned by their variant recognition profiles whereby β4 mAbs
are specific for hCG (≤1 % cross-reactivity with hLH) and β5 mAbs
strongly cross-react with hLH (>>1 %) in titration and competitive RIA
(Fig. 4). β3-mAbs, although showing a similar reaction pattern as other
mAbs directed to hCGβ loops 1+3 associated epitopes (β2, β4, β5, and
β6), seems to be remote from the free subunit specific epitope β6 and
not compatible with hCGβCTP113-116 located epitope β9 at the be-
ginning of hCGβCTP. Such spatial vicinity between the hCGβCTP and
hCGβ loop 3 has already been postulated previously [72]. As expected,
the epitope of β8-mAbs located at the very carboxyl-terminal end of
hCGβ (aa hCGβ141-144; [24]) is compatible with all other epitopes. In
the first ISOBM TD-7WS, a new epitope β14 was observed represented
by a single mAb (ISOBM-267) that exclusively recognized core hCGβ
[1] and that now appeared compatible with all hCGβ located epitopes
except for epitope β1, thus seems to be remote from any other core
hCGβ epitope. ISOBM-406 according to its sandwich pattern (no
compatibility with cystine knot epitopes β1 and β7) seems to be cystine
knot associated. b c-mAbs show variant reaction patterns among them-
selves. The heterodimeric epitopes c1–c3 are located in the same anti-
genic domain thus are not compatible with each other. c4 is clearly
remote from that domain as it is compatible with c1 to c3-mAbs.
ISOBM-433 recognizes a previously structurally not defined epitope
that is highly hCG specific as is ISOBM-446 (epitope c3) (Fig. 4).
ISOBM-389 a highly hCG specific c-mAb that according to BIAcore®
analyses rapidly dissociates (Kd=13E−03), ISOBM-397 and ISOBM-
418 (very low affinity in FRET analyses) did not perform well as
capture mAbs in this type of assay and were negative throughout (not
shown). Reactions classified as positive (mean+2 standard deviations)
are depicted as closed squares. Noncompatible mAb pairs are shown as
white squares

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are pan hCG specific, i.e., present on hCG, hCGn, hCGβ
hCGβn, and hCGβcf (Fig. 4a), whereas β6 is present only
on hCGβ, hCGβn, and hCGβcf.
The cystine knot-associated antigenic domain comprises a
number of epitopes that are recognized by 10 of the 48 β-
mAbs (including ISOBM-397 results of which are ambigu-
ous). ISOBM-267 that is hCGβ specific and its epitope
cystine knot-related (epitope β14) was used as a control
mAb: The pan-hCG epitope, β1 (hCGβ Arg10, Arg60, and
Gln89), which is not shared by hLH, was recognized by two
ISOBM-mAbs (ISOBM-403 and reference mAb ISOBM-
435). It is spatially close to epitope β7 (hCGβ Asp61 and
Gln89) against which six mAbs (including ISOBM-397) were
directed. MAbs classified as β7 recognize either hCGβ+-
hCGβn+hCGβcf or mainly hCGβ+hCGβn (ISOBM-407).
The cystine knot-related epitope β10 recognized by reference
mAb ISOBM-448 is hCGβcf specific. One mAb (ISOBM-
406) reacted with a not specified cystine knot epitope
(Fig. 6a). This mAb is of restricted pan-hCG specificity and
does not recognize hCGβcf (Fig. 4a).
In addition to the above-mentioned mAb ISOBM-448 (cys-
tine knot related epitope β10), 4 of the 48 β-Abs recognize
epitopes located on hCGβcf only (epitope β11, ISOBM-384
and ISOBM-444; epitope β13, ISOBM-443; and one non-
coded hCGβcf epitope, ISOBM-393).
Six of the 48 β-Abs are directed against the hCGβCTP.
The linear antigenic region (aa hCGβ137–144; epitope β8)
at the very end of the hCGβCTP is recognized by four
mAbs; type 2). Three of these (ISOBM-395, ISOBM-413,
and ISOBM-420) are mAbs against epitope β8,2 recognizing
glycosylated hCGβ much better than the nonglycosylated
synthetic peptide. Thus, epitope β8,2 might be influenced by
glycans on Ser132 and/or Ser138 [1, 39]. One mAb
(ISOBM-450; epitope β8,1) recognizes both antigens to the
same extent. Two mAbs, 394 and 418, may be directed
against epitope β9. One β-mAb (ISOBM-392) could not be
classified but it does not seem to be located on hCGβCTP
(Figs. 4a and 7a).
Thirteen of the 69 mAbs reacted with c-epitopes: c1
(n=2), c2 (n=6), c3 (n=1), c4 (n=2), c (n=1; ISOBM-433;
new noncoded c-epitope). One c-mAb could not be classified
(ISOBM-389).
Eight out of 69 mAbs are directed against hCGα. Six
recognize assembled and one, ISOBM-404, which has been
prepared by immunization with hCGα (Stenman et al.,
unpublished data), recognizes only free hCGα. The exact
molecular localization of the hCGα mAbs was not elucidat-
ed (Figs. 4b and 7b).
Discussion
Topography of hCG epitopes
Epitopes and antibodies
By definition, epitopes are molecular structures dependent
on the existence of complementary Abs. Not the entire
surface of a glycoprotein like hCG is antigenic. Against
certain molecular areas no Abs exist as they are immunolog-
ically inert, e.g., due to insufficient T cell help, or sterically
not accessible due to protein folding or shielding by glycans.
In contrast, other areas representing structurally inherent
epitopes, which are characterized by high solvent accessibil-
ity and high protrusion indices, are often sites of Ab recog-
nition [40]. hCGβ cystine knot-associated residues Arg10
and Gln89 (epitopes β1 and β7), hCGα loop 1 residues
Pro16, Phe17, and Phe 18 (epitopes α1, α2,and α4) and the
antigenic domain on hCGβloops 1+3 comprising aa 20–
25+68–75 (epitopes β2–β6) all bulge away from the mole-
cule forming prominent surfaces that are the major antigenic
domains of hCG [3, 22, 37, 41–43]. There is a good chance
that irrespective of the immunized species these molecular
structures will be recognized as epitopes [38]. For example,
Tracer mAbs
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the immunodominant antigenic domain on top of hCGβ
beta-sheet loops 1 and 3 is recognized by Abs derived from
mice and sheep as shown in the present study and interest-
ingly by Abs from humans and rabbits (PB, unpublished
observations). Moreover, hLH cross-reactive mAb B206
directed against an epitope within this cluster, presumably
epitope β3/5, inhibited 40–90 % of the binding of human
antisera to hCG [44].
The definition of epitopes by Abs and recognition of the
multitudes of possible amino acid combinations within an
inherently antigenic structure/domain is dependent on and
restricted by the combinatorial repertoire of the VDJ and VJ
immunoglobulin heavy and light chains gene segments, re-
spectively, and the cellular capacity to mature the paratope of
a given Ab to optimally fit the antigenic surface. This reper-
toire of Ab specificity varies with individual immune re-
sponses, haplotypes, and species. Not every amino acid
combination within an antigenic domain will therefore be
recognized by Abs of any individual or species. Thus, the
repertoire of Ab specificities and corresponding epitopes
within an antigenic domain is very large but still somewhat
restricted as shown by the present and previous studies. For
example, the antigenic domain on hCGβ loops 1+3 is rec-
ognized by large panels of Abs that differ slightly in hCG
variant recognition, hLH cross-reactivity, affinity, etc. This
has been shown to be due to variability in amino acid
recognition within the antigenic domain [1].
It is striking that this antigenic region, aa hCGβ20–
25+68–75 on the tips of loops 1+3, comprises 16 amino
acids, a number that reasonably well corresponds to the
surface covered by a single complementary paratope of an
Ab whereby two to three amino acids that vary from Ab to
Ab provide most of the binding energy and fine specificity
[45]. Consequently, dozens of ISOBM-mAbs and Abs of
other panels directed against hCGβ loops 1+3 epitopes
β2–β5 do not behave uniformly in their recognition of the
approximately 15 potential contact amino acids composing
discontinuous epitopes, even though they cover more or less
the same surface with their paratope [43]. Thus, all differ-
ences in affinity, specificity, and hLH cross-reactivity of
numerous antibodies directed against this major antigenic
region seem to have their basis in variability of preferential
Table 5 Epitope assignment of the ISOBM-Abs using three approaches
Epitopes n Comments Classification of ISOBM-mAbs by three approaches
β-mAbsa 48 Antigen binding (NRH) Affinity (FRET) (ABB) Sandwich assay (NRH)
β1 2 Specific for hCG and hCG derivatives 403, 435* 403, 435* 403, 435*
β2,β4 12 <1% cross-reactivity with hLH/hLHβ
Epitopes located on top of loops 1+3
β2: 382, 388, 390, 402, 408, 
416, 417, 426, 427, 449*
β4: 419, 445 *
β2: 382, 388, 390, 402, 408, 
416, 417, 426, 427, 449*
β4: 419, 445*
β2: 382, 388, 390, 402, 408, 416, 
417, 426, 427, 449*
β4: 419, 445*
β3,β5 13 High cross-reactivity with hLH/hLHβ
Epitopes located on top of loops 1+3
β3: 396, 399, 400, 401, 405, 
424, 434, 441*
β5: 428s to 431s, 442*
β3: 396, 399, 400, 401, 405, 
424, 434, 441 
β5: 428s to 431s, 442*
β3: 396, 399, 400, 401, 405, 424, 
434, 441*
β5: 428s to 431s, 442*
β6 2 No recognition of the αβ heterodimer 410, 437 410, 437 410, 437
β7 6 No recognition of the αβ heterodimer 386, 397, 407, 409, 415, 439 386, 397, 407, 409, 415, 439 386, 407, 409, 415, 439
β8 4 Epitope on hCGβCTP Type 1: 450*; 
Type 2: 395, 413, 420
450*, 395, 413, 420 450, 395, 413, 420
β9 2 Epitope on hCGβCTP 394, 418 394
β10-β13 5 Specific for hCGβcf 384, 393, 443*, 444*, 448* 384, 444* n.d.
β 2 Unspecified location 392, 406 392, 406 (cystine knot?)
-mAbsb 13
c1 2 In a cluster with c2, sensitive to nicks 414, 447* 414, 447* 414,447*
c2 6 In a cluster with c1, sensitive to nicks 387, 411, 422, 425, 436*, 438* 387, 411, 422, 425, 436*, 438* 387, 411, 422, 425, 436*, 438*
c3 1 Specific for hCG + hCGn 446* 446* 446*
c4 2 Spatially remote from other epitopes 424, 440* 424, 440* 424, 440*
c 2 Unspecified location 389, 433 389 433
α-mAbsc 8 Not epitope typed in detail 383, 385, 391, 398, 404, 412, 
421, 432
α3 1 Epitope sensitive to iodination 432?
α6 1 Specific for non-combined hCGα 404?
Excluded Abs None 383d, 385d, 391d, 398d, 404d, 
412d, 418d, 421d, 432d, 443*d,
448*d
383, 384, 385, 389e, 391, 393, 397, 
398, 404, 412, 418e, 421, 432e, 
434e, 443*, 444*, 448*
a Fourteen epitopes, 13 of which recognized by ISOBM-mAbs
b At least four epitopes; four plus one recognized by ISOBM-mAbs
c Seven epitopes; these ISOBM-mAbs were not characterized in detail
d Specificity based on affinity for hCG, hCGβ and hCGβcf could not be determined
e These four ISOBM-mAbs did not perform well as capture reagents
*Reference mAbs
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recognition of a few amino acids, providing binding energy
within very similar or even identical sets of amino acids
covered by the Abs’ paratopes.
The surface area of an epitope that is covered by a
cylinder-like antigen binding site of an Ab is approximately
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binding domain is 8–10 Å and the radius of the epitope
covering area is 15 Å irrespective of Ab specificity [45]. X-
ray crystallography studies revealed that core hCG, i.e., hCG
without hCGβCTP, has a length of 75 Å and a width of 30–
35 Å [3, 47] corresponding to a surface area of approximately
8,200 Å2. As some regions on assembled hCGβ, such as the
stems of β-sheet loops 1+3, are not recognized by any anti-
hCG-mAbs [1, 18, 48], the total epitope-covered area on core
hCG could be in the range of 5,000 Å2 theoretically accommo-
dating simultaneous binding of up to seven Abs to spatially
independent epitopes. The minimal spatial requirement for
sterical compatibility of two mAbs is that the respective epi-
topes are approximately 20–30 Å apart. In fact preliminary
experiments showed that at least five radiolabeled mAbs
against epitopes β1+β3+α2+α3+c4 were able to bind to core
hCG simultaneously [38].
Glycosylation and epitopes
With two exceptions, glycosylation has little effect on hCG’s
immunological make-up, although the glycans, which are
hydrophilic in nature and thus surface exposed, represent
approximately 30–35 % of its total molecular mass. The
exceptions are glycans at the very end of hCGβCTP and in
the stem region of hCGβ loop 1. The 14 epitopes on core
hCG, which is lacking hCGβCTP, are dependent on the
protein backbone. Neither desialylation, deglycosylation
[48], partial natural deglycosylation as in the case of the
metabolic product hCGβcf [49], nor intense glycosylation
as shown with highly acidic pI variants of pregnancy- and
tumor-derived hCG have essential effects on Ab recognition
by the reference mAbs [17, 18]. In addition, the number and
the relative spatial location of epitopes do not differ between
the isoforms [1, 18, 48].
The peptidic stem region of assembled hCGβ loop 1,
which accommodates the two large N-linked glycans at
hCGβAsn13 and Asn30 that are spatially near the hCGα
glycan at Asn52 [3], is not recognized by any mAb in the
panels of anti-hCG-mAbs of the previous and the present
study. Thus, the immune response seems to be attenuated
by the N-linked glycans in this region of hCGβ loop 1
[1, 18, 48].
A mAb (B152) that was not included in this study
recognizes hCG with a core-2 O-glycan at Ser 132 and
surrounding peptide structures [50, 51]. Its epitope,
which we termed β8,3, is spatially related to epitope β8,2 that
also seems to be influenced by the glycans on Ser 132 and/or
Ser 138 [1, 29].
Some hCG assays have been claimed to underestimate
hCG-h [52]. However, these results have been obtained with
an hCG-h preparation that also was completely nicked (C5)
[39]. Thus, the results most probably reflected failure to
recognize hCGn rather than hyperglycosylated hCG.
Epitopes on assembled and/or free hCGβ (β1–β9, β14)
and hCGβcf only (β10–β13)
The immunodominant structure of hCG and hCGβ-related
molecules is the molecular region corresponding to hCGβcf,
which has lost its N-terminus, the long loop 2, most of its N-
linked carbohydrate antennae, and the hCGβCTP with all O-
linked glycans but has retained its protein backbone config-
uration [53]. Thus, numerous mAbs against epitopes β1–β7
recognize hCGβ, hCGβn, and hCGβcf. However, one mAb
(ISOBM-407) did not react with hCGβcf.
The epitopes on assembled and/or free hCGβ (β1–β9,
β14) are located in three molecular regions: (1) hCGβ cystine
knot, (2) tips of hCGβ loops 1+3, and (3) hCGβCTP.
The cystine knot-associated antigenic domain includes
epitope β1 involving aa hCGβArg10+Arg60 and possibly
Gln89 that sterically are in close proximity to each other [42,
43]. hCGβArg10 and Gln89 are unique to hCG and not
shared by hLH. This presumably explains why epitope β1
is highly specific for hCG and its variants and therefore is not
Fig. 7 Epitope maps of hCG, hCGβ, and variants (INN) (modified
according to [1], with permission) were previously constructed based
on the epitopes recognized by the reference mAbs. The identification of
reference mAb epitopes was performed by direct binding, competitive
and sandwich RIA and ELISA with hormones of various species, hor-
mones subunits, metabolic breakdown products, and synthetic peptides
(for reviews, see [1, 22]). Furthermore, on the basis of molecular model-
ing of crystallographic data of hCG and subsequent mutational analyses
to assign epitopes to particular amino acids, epitopes of reference mAbs
and, by comparison, epitopes of ISOBM-mAbs could be superimposed
on the molecular model of hCGβ. a Assignment of ISOBM-mAbs to
epitopes on the molecular model of hCGβ/hCGβn/hCGβcf/hCGβCTP.
Reaction profiles of the ISOBMii mAbs in specificity and sandwich
assays were compared to that of reference mAbs. It appeared that the
most immunogenic region of hCGβ is determined by the peptide se-
quences that correspond to hCGβcf. In particular, the tips of beta-sheet
loops 1+3 corresponding to hCGβ20-25+68–77 comprise the major
antigenic domain (epitopes β2–β6) that is recognized by high affinity
mAbs. The only hCG-specific epitope on core hCGβ isβ1 located around
the center of the molecule corresponding to part of the cystine knot (aa
hCGβ10,60,89). Adjacent to epitope β1, the hCGβ/hCGβcf-specific
epitope β7 is also located in this region (aa hCGβ61,89) [43]. Thus, pairs
of antibodies against these two epitopes are not compatible in sandwich
type assays (Fig. 6a) [24]. hCGβCTP epitopes β9 and β8 are located at
either end of the hCGβCTP, whereby β9 might be close to epitope β3
(Fig. 6a) [72]. b Epitope map of hCG. ISOBM-mAbs were assigned to
epitopes on a ribbon representation of the molecular model of hCG [3].
hCGα and epitopes thereon are depicted in blue, hCGβ and its epitopes in
green. Conformationally (c) dependent epitopes determined by the qua-
ternary structure of hCG are shown in red. Note the major antigenic
clusters of epitopes on the top of beta sheet loops 1 and 3 of hCGα (α1/
α2/α4 and α3/α5) and of hCGβ (β2– β5), the central cystine knot-based
epitope cluster encompassing highly hCG-specificβ1 and c-epitopes (c3),
the latter having a share on loop 2 of hCGβ, that in turn are confluent with
the α1/α2/α4 epitope cluster. The hCGβCTP epitopes are located on both
of its ends at aa hCGβ113-116 (epitope β9) and aa hCGβ133-144
(epitope β8)

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present on hLH or hLHβ [26]. Due to its superior specificity,
it is highly valuable for hCG/hCGβ-variant measurement by
immunoassay with no interference by hLH or hLHβ [1].
The assumed location of epitope β7 on hCGβ, hCGβn,
and hCGβcf is based both on mutational analyses and
vicinity analysis by sandwich assays: It is associated with
the cystine knot, present on hCGβcf, and Asp61 and
Gln89 have a role in this epitope. Thus, in sandwich type
assays, β7-mAbs are not compatible with β1-mAbs
(Fig. 6a) [1, 22, 24].
MAbs against the cystine knot epitope β7 recognize
hCGβcf in addition to hCGβ. ISOBM-407 is an exception
to this, although other parameters match with epitope β7, it
shows an exceptionally low cross-reactivity with hCGβcf
(Fig. 4) and thus seems to be suitable for measurement of
hCGβ in urine in the presence of high levels of hCGβcf.
The assignment of hCGβ specific epitope β14 to the cystine
knot antigenic domain is based on circumstantial evidence
as mAb ISOBM-267 defined in the First ISOBM TD-7 WS
to recognize epitope β14 is not compatible with
hCGβcystine knot-related epitope β1 but with all other
hCGβ-related epitopes (Fig. 6a). Two hCGβcf epitopes
β10 and β12 are also cystine knot-associated (PB,
unpublished data). An additional cystine knot-related epitope
is represented by mAb ISOBM-406.
Antibodies directed against the major hCGβ antigenic
domain on loops 1 and 3 are of significantly higher affinity
compared to those against other antigenic regions of
hCGβ[1, 21, 54]. MAbs against epitopes β2–β5 recognize
a wide spectrum of hCG and hCGβ-related variants (hCG,
hCGn, hCGβ, hCGβn, and hCGβcf) [1, 17, 18]. MAbs
against epitopes β3 and β5 additionally react well with
hLH and hLHβ, whereas epitopes β2 and β4 are specific
for hCG and hCGβ variants (<1 % hLH and hLHβ cross-
reactivity) and thus highly suitable for specific measurement
of hCG and hCGβ variants (Fig. 4) [1, 26].
In summary, β-epitopes located on the protein core
hCGβ1-112 are discontinuous in nature, determined by the
tertiary protein structure, present on hCGβcf, and arranged
in antigenic domains associated with the cystine knot
and on the tips of loops 1+3. MAbs directed against these
epitopes are of adequate affinity and suitable for immunoassay
applications.
hCGβ-related epitopes not determined by hCGβcf or core
hCGβ1–112 are located in two major regions on the hCGβCTP
(aa hCGβ113–145). The immunodominant linear antigenic
region at the very end of the hCGβCTP consists of aa
hCGβ133–144 and encompasses epitope β8 that is composed
of epitope variants β8,1, β8,2, and β8,3) [29, 55]. It partially
seems to be influenced by glycans on Ser132 and/or Ser138
(epitopes β8,2 and β8,3) [29] [1, 50]. One mAb in this WS
(epitope β8,1; ISOBM-450) and four mAbs in the First WS
recognized nonglycosylated synthetic peptides and
glycosylated hCGβ equally [1]. Epitope β9 at aa hCGβ113–
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a Candidate mAbs for the respective epitopes are listed in Figs. 4, 6, 7, and Appendix 2
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116 [21, 24] was recognized by two mAbs (Fig. 7a) whereby
ISOBM-394 was of high and ISOBM-418 of very low affinity
(Fig. 5).
When immunizing with the glycoprotein hCG, the vast
majority of antibodies will be generated against composite
epitopes on hCGα or the core region of hCGβ (aa 1–112) but
only rarely against linear peptide sequences of low structural
order like the hCGβCTP. MAbs against hCGβCTP are
generally of fairly low affinity. Nevertheless, they are used
in diagnostic sandwich-type immunoassays as they do not
cross-react with hLH (Fig. 4).
hCGα epitopes (α1–α7)
In the panel of ISOBM-mAbs, 8 of 69 recognize hCGα
epitopes. One of these mAbs, ISOBM-404, seems to be
specific for free hCGα, and it is speculated that it might
recognize the sequence hCGα33-42 on the single loop 2. As
no reference hCGα-mAbs (Table 2) were included, a de-
tailed assignment of epitopes was not possible.
Epitopes on the hCG αβ-heterodimer (c1–c4)
At least four epitopes (c1–c4) are present only on hCG±-
hCGn but not on either free subunit or hCGβcf [21, 26, 28].
Detailed analysis of hCG and hCGn recognition by the
ISOBM-mAbs was performed by liquid chromatography
mass spectrometry (LC-MS/MS) (see accompanying publi-
cation by H. Lund). Epitopes c1 (reference mAb INN-hCG-
10) and c2 (reference mAbs INN-hCG-40 and INN-hCG-53)
are (1) dependent on intact hCG and thus sensitive to nicking
of assembled hCGβ loop 2, (2) not compatible in sandwich-
type assays with the cystine knot-related hCGβ epitope β1
(aa hCGβArg10+Arg60 and possibly Gln89) [38], and (3)
incompatible with mAbs recognizing epitope cluster α1, α2,
and α4 [38] on loop 1 in the region of aa hCGα13-22. Amino
acids hCGβ44-48 in loop 2 and hCGα loop 1 have been
shown by X-ray crystallography to be in close proximity as
the subunits are assembled in a head-to-toe fashion [3]. It is
striking that in sandwich assays c1-mAbs show identical
reactivity patterns as α1- and α2-mAbs reflecting sterical
epitope relatedness [28, 38].
MAbs against epitope c3 are sterically related to epitope
c2, highly specific versus hLH as well as non-combined
intact and modified subunits (<1 % cross-reactivity), not
influenced by nicking of assembled hCGβ loop 2, and thus
recognize hCGn and hCG equally [1, 56](Fig. 4). They are
therefore highly suitable for simultaneous measurement hCG
and hCGn (Table 6).
The exact molecular localization of epitope c4 has
not been resolved yet. It is present on hCGn and
hLH, remote from and thus sterically compatible with
all other c-epitopes and to a minor extent determined by
hCGβ as shown by low cross-reactivity [1, 26, 38]. A
variant of the c4-epitope represented by ISOBM-424 (=
ISOBM-279, First ISOBM TD-7 WS) that is not shared
with hLH (cross-reactivity <0.1 %) seems to exist. A
presumably fifth highly specific c-epitope has been ob-
served in sandwich assays wherein mAb ISOBM-433 is
compatible with mAbs to c1–c4 (Fig. 6b). Its molecular
localization is unknown. ISOBM-389 is a c-mAb that
could not be epitope typed but, according to its speci-
ficity profile analyzed by LC-MS/MS, might be a c2
mAb (see accompanying publication by H. Lund).
Method-specific recognition of hCG and hCG variants
Sandwich-type assays measuring hCG alone or in com-
bination with free hCGβ and metabolites are used for
detection of pregnancy, pregnancy-related disorders, tro-
phoblastic disease, and various other female and male
tumors [2]. Detailed knowledge of the epitopes recog-
nized by the Abs used facilitates development of assays
providing better comparability of the results between
methods. It has been suggested that assays that are mul-
tifunctional with respect to clinical use should (1) recog-
nize in an equimolar fashion hCG and hCGβ protein
backbone and glycosylation variants, (2) not cross-react
with hLH or derivatives, and (3) not be prone to signal
blunting by non-measured variants, e.g., caused by ex-
cess hCGβcf leading to false low results [36]. This is a
problem when hCG in urine is measured with sandwich
assays utilizing a mAb against core hCGβ1-112 in com-
bination with an anti-hCGβCTP mAb [57].
While assays measuring hCG and all hCGβ-related vari-
ants are useful as first line methods, for diagnosis of pregnan-
cy and cancer, it is often advantageous to specifically measure
only selected variants [2]. Thus, specific hCGβ assays are
used for first trimester Down’s syndrome screening and also
for diagnosis of testicular [58, 59] and nontrophoblastic can-
cers, 20–50 % of which produce only hCGβ but not hCG
[60–62]. However, the concentrations are mostly low, and the
assays used need to be highly sensitive. Assays for hCGβ that
are intended for first trimester screening of Down’s syndrome
need to be insensitive to interferences by an approximately
100-fold excess of hCG and tuned to measure fairly high
concentrations. They are therefore of limited utility for the
diagnosis of nontrophoblastic cancers.
Elevated plasma concentrations of hCGβ are reflected by
high levels of hCGβcf in urine [63], and specific assay of
this form has been used for diagnosis of nontrophoblastic
cancer [62, 64, 65] and for the characterization of the First
IRR for hCGβcf [9]. However, commercial assays are not
available presently.
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Candidate epitopes for measurement of hCG and hCGβ
Assays specifically recognizing hCG, hCGβ, and related
variants can be constructed using a combination of two pan
hCGβmAbs with identical specificity profiles [66], i.e., with
one partner directed against epitopesβ2 orβ4 (the hCGβloops
1 and 3 domain) combined with a mAb-recognizing epitope
β1 (the hCGβ cystine knot domain; Table 6).
In the two ISOBM TD-7 WSs, 50 of 96 Abs were shown to
recognize hCG+hCGβ and 23 of these did not recognize hLH.
Theoretically, any of the five mAbs directed against epitope β1
around the cystine knot could be combined with any of the 18
mAbs against epitopes β2 or β4 on loops 1+3 for construction
ofmultifunctional assays. Epitopesβ1 andβ2/4 are shared by all
important hCG and hCGβ protein backbone variants and gly-
cosylation isoforms including hCG-h and hCGβ-h [17, 18].
MAbs against these two discrete epitopes are highly specific for
hCG with <0.1 and <1 % cross-reaction for hLH for epitopes
β1 and β2/4, respectively. No other epitope combination pro-
vided assays with equally wide and identical recognition of
hCG and hCGβ variants and high specificity versus hLH.
While Abs recognizing these epitopes provide desirable
specificity, variable affinity for hCG variants (Fig. 5) may cause
nonequimolar recognition of hCG and hCG variants in different
methods [6]. Although assay specificity can be predicted on the
basis of mAb specificity profiles and epitope recognition [66],
ultimate performance can only be evaluatedwith the final assay.
An additional source of method variability in hCG measure-
ment that cannot be fully predicted is that of Ab synergy, which
may vary between different Ab pairs [67].
Alternative epitopes for measurement of hCG and/or hCGβ
and variants
Few manufacturers provide information about the epitope
specificities of Abs used in their assays, but due to variable
recognition of the First IRR preparations for hCG and vari-
ants, it is obvious that different epitope combinations are used
in the major commercial assays [6]. In addition to the epitope
combination β1–β2/4, other combinations are possible for the
construction of assays for hCG and variants, e.g., epitopesβ8,1
and β2, β1–α5, α4–β2, etc., but none of them will fulfill all
three above-mentioned criteria. However, the frequently used
β8 and β2 combination does not pose problems as long as
serum specimen are measured that do not contain hCGβcf,
truncated hCG or truncated hCGβ, or clipped hCGβCTP.
For selective measurement of hCG or free hCGβ or
hCGβcf certain epitope combinations can be suggested: for
hCG (no recognition of hLH or noncombined subunits), a
mAb against epitope c2 or c3 can be combined with one
against β2/4 (Table 6). Alternatively, β1–α3 combinations
[66] orβ2/4 combined with a tracer mAb against anα epitope
are possible [68]. These designs eliminate cross-reactions
with free subunits but are sensitive to interferences by free
subunits and hCGβcf. For measurement of free hCGβ, a
mAb to epitope β7 or β14, and for hCGβcf, a mAb to epitope
β11 can be combined with one to epitope β2/4. For hCGα,
combinations of mAbs against epitopes α6 and α5 are rec-
ommended [69] (Table 6).
A unique mAb coded B152 is used for the measurement
of hCG-h that carries a core-2 glycan on Ser132 located on
hCGβCTP [20]. However, the clinical utility of assays using
this mAb remains to be established [70].
Future perspectives: harmonization of hCG and/or hCGβ
and variant measurement
Considerable reduction in between-method and between-
laboratory variability in results can be achieved by a number
of measures: (1) the establishment and usage of a clear nomen-
clature of hCG and its variants [1, 8]; (2) endorsement of that
nomenclature to define what hCG-assay measure [1, 8, 60]; (3)
characterization of diagnostic assays with the new six First
IRRs calibrated in SI units that were adopted by WHO for
immunoassay standardization [6]; (4) standardization of
methods with the highly pure new WHO Fifth IS for hCG
encoded 07/36,4 which is identical to the First IRR for hCG
99/688; (5) harmonization of mAb epitopes used in diagnostic
methods for hCG, hCGβ, and their variants; and (6) the estab-
lishment of referencemethods for the various forms of hCG [8],
which will be supported by the detailed knowledge on Ab
epitope recognition reported in the present study.
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Appendix
Table 7 ISOBM-TD-7 Abs submitted to Dr. Kjell Nustad
ISOBMii  




383 Medix 5501 SP-1
384 Stenman F52-3F8
385 Medix 5503 SPI
386 Stenman F94-8F8
387 Medix 5009 SP-5
388 Medix 5006 SP-5
389 Stenman F140-11C5
390 Medix 5008 SP-5
391 Medix 6601 SPR-5
392 Stenman F20-6E11
393 Stenman F52-3C11








402 Medix 5004 SP-1
403 Roche M-INN2 265,274,435 I.C.
404 Stenman F26-7E10
405 Stenman F95-1B2
406 Medix 5011 SPRN-1
407 Stenman F19-9C11
408 Medix 5016 SPRN-5
409 Medix 5012 SPRN-1
410 Roche M-BCG005




415 Siemens 3A11 281 I.C.
416 Paus E30 273 I.C.
417 Roche M-INN22 276.449 I.C.
418 Siemens 2F11 280 I.C.
419 Paus E27 271 I.C.
420 Roche M-94.139 277, 264 I.C.
421 Siemens 41I/100.1.1.200.4.2
422 Paus E28 272 I.C.
423 Mologic D102
424 Siemens 1G4 279 I.C.
425 Siemens 5 E 5




428 sheep Mologic 8F11 sheep
429 sheep Mologic 9F10 sheep
430 sheep Mologic 8G5 sheep
431 sheep Mologic 618 sheep poly
434a INN hCG111 Ref
435a INN hCG2 265,274,403 Ref
436a INN hCG40 Ref
437a INN hCG64 Ref
438a INN hCG53 Ref
439a INN hCG68 Ref
440a INN hCG26 Ref
441a INN bLH1 Ref
442a INN hCG58 Ref
443a INN hCG112 Ref
444a INN hCG106 Ref
445a INN hCG24 Ref
446a INN hCG45 Ref
447a INN hCG10 Ref
448a INN hCG103 Ref
449a INN hCG22 276.417 Ref
450a Stahli h54 Ref
I.C. Internal control
a Reference antibodies
Table 8 Abs grouped according to epitope recognition
ISOBMii  
Ab Codes Owner Owner Codes
ISOBMi&ii 
Codes Controls Epitope
403 Roche M-INN2 265,274,435 I.C.
435a INN hCG2 265,274,403 Ref
382 Stenman F16-6G5
388 Medix 5006 SP-5
390 Medix 5008 SP-5
402 Medix 5004 SP-1
408 Medix 5016 SPRN-5
416 Paus E30 273 I.C.
417 Roche M-INN22 276.449 I.C.
426 Siemens 16 E 2
427 Siemens 34A8.1.1







434a INN hCG111 Ref
441a INN bLH1 Ref
419 Paus E27 271 I.C.
445a INN hCG24 Ref
428 sheep Mologic 8F11 sheep
429 sheep Mologic 9F10 sheep
430 sheep Mologic 8G5 sheep
431 sheep Mologic 618 sheep poly
442a INN hCG58 Ref
410 Roche M-BCG005




409 Medix 5012 SPRN-1
415 Siemens 3A11 281 I.C.
439a INN hCG68 Ref
450a Stahli h54 Ref
395 Abbott 71752
413 Mologic D101
420 Roche M-94.139 277, 264 I.C.
394 Medix 5014 SPTN-5
418 Siemens 2F11 280 I.C.
392 Stenman F20-6E11
406 Medix 5011 SPRN-1
384 Stenman F52-3F8
393 Stenman F52-3C11
443a INN hCG112 Ref
444a INN hCG106 Ref
448a INN hCG103 Ref
414 Paus E26
447a INN hCG10 Ref
387 Medix 5009 SP-5
411 Roche M-1F7.9 275 I.C.
422 Paus E28 272 I.C.
425 Siemens 5 E 5
436a INN hCG40 Ref
438a INN hCG53 Ref
446a INN hCG45 Ref c3
424 Siemens 1G4 279 I.C.
440a INN hCG26 Ref
389 Stenman F140-11C5
433 Medix 45A10
383 Medix 5501 SP-1
385 Medix 5503 SPI
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